Matinas BioPharma is a biotechnology business based in the US. Matinas BioPharma shares (MTNB) are listed on the NYSE MKT and all prices are listed in US Dollars. Its last market close was $0.54 – a decrease of 14.88% over the previous week. Matinas BioPharma employs 32 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.54 |
|---|---|
| 52-week range | $0.50 - $18.49 |
| 50-day moving average | $2.88 |
| 200-day moving average | $7.82 |
| Wall St. target price | $30.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-5.50 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.565 from 2024-11-19
| 1 week (2024-11-14) | -10.94% |
|---|---|
| 1 month (2024-10-21) | -84.85% |
| 3 months (2024-08-21) | 422.18% |
| 6 months (2024-05-21) | 242.42% |
| 1 year (2023-11-21) | 163.77% |
|---|---|
| 2 years (2022-11-21) | -98.29% |
| 3 years (2021-11-19) | 52.5 |
| 5 years (2019-11-21) | 58.5 |
| Gross profit TTM | $-13,490,000 |
|---|---|
| Return on assets TTM | -50.87% |
| Return on equity TTM | -97.59% |
| Profit margin | 0% |
| Book value | $3.81 |
| Market Capitalization | $3.2 million |
TTM: trailing 12 months
We're not expecting Matinas BioPharma to pay a dividend over the next 12 months.
Matinas BioPharma's shares were split on a 1:50 basis on 2 September 2024 . So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Matinas BioPharma shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Matinas BioPharma shares which in turn could have impacted Matinas BioPharma's share price.
Over the last 12 months, Matinas BioPharma's shares have ranged in value from as little as $0.5 up to $18.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Matinas BioPharma's is 1.728. This would suggest that Matinas BioPharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Matinas BioPharma Holdings, Inc. , a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead's remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.